Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANAB NASDAQ:PHVS NASDAQ:TSHA NASDAQ:UPB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$62.19-0.8%$62.75$11.40▼$72.36$1.82B0.79777,529 shs469,518 shsPHVSPharvaris$30.70-6.8%$28.07$15.34▼$33.33$2.15B-2.34381,846 shs480,550 shsTSHATaysha Gene Therapies$6.30-5.5%$5.29$2.25▼$7.30$1.92B1.252.69 million shs1.85 million shsUPBUpstream Bio$8.79-6.1%$9.23$7.25▼$33.68$509.37M1.28519,213 shs568,770 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio-0.80%-7.12%-11.44%+17.16%+219.74%PHVSPharvaris-6.80%+3.44%+7.04%+16.07%+91.04%TSHATaysha Gene Therapies-5.55%-5.55%+33.76%+38.46%+165.82%UPBUpstream Bio-6.09%-2.12%-14.99%+0.46%+2.69%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$62.19-0.8%$62.75$11.40▼$72.36$1.82B0.79777,529 shs469,518 shsPHVSPharvaris$30.70-6.8%$28.07$15.34▼$33.33$2.15B-2.34381,846 shs480,550 shsTSHATaysha Gene Therapies$6.30-5.5%$5.29$2.25▼$7.30$1.92B1.252.69 million shs1.85 million shsUPBUpstream Bio$8.79-6.1%$9.23$7.25▼$33.68$509.37M1.28519,213 shs568,770 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio-0.80%-7.12%-11.44%+17.16%+219.74%PHVSPharvaris-6.80%+3.44%+7.04%+16.07%+91.04%TSHATaysha Gene Therapies-5.55%-5.55%+33.76%+38.46%+165.82%UPBUpstream Bio-6.09%-2.12%-14.99%+0.46%+2.69%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANABAnaptysBio 2.85Moderate Buy$78.7326.59% UpsidePHVSPharvaris 2.69Moderate Buy$49.1860.20% UpsideTSHATaysha Gene Therapies 3.00Buy$11.6484.70% UpsideUPBUpstream Bio 2.40Hold$38.75340.84% UpsideCurrent Analyst Ratings BreakdownLatest UPB, ANAB, TSHA, and PHVS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2026UPBUpstream Bio MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$51.00 ➝ $50.005/13/2026ANABAnaptysBio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/13/2026ANABAnaptysBio UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $76.005/13/2026PHVSPharvaris UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$74.005/13/2026ANABAnaptysBio BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$63.00 ➝ $75.005/13/2026PHVSPharvaris Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$75.00 ➝ $74.005/6/2026UPBUpstream Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/4/2026ANABAnaptysBio Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/4/2026ANABAnaptysBio Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$95.00 ➝ $93.004/28/2026ANABAnaptysBio Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$66.00 ➝ $85.004/22/2026ANABAnaptysBio BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$79.00 ➝ $63.00(Data available from 5/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANABAnaptysBio$234.60M7.71N/AN/A$0.44 per share141.34PHVSPharvarisN/AN/AN/AN/A$4.23 per shareN/ATSHATaysha Gene Therapies$9.77M185.30N/AN/A$0.74 per share8.51UPBUpstream Bio$2.85M167.84N/AN/A$6.29 per share1.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANABAnaptysBio-$13.23M-$1.08N/A20.06N/A-11.53%-1,101.24%-7.75%N/APHVSPharvaris-$198.79M-$3.18N/AN/AN/AN/A-67.56%-61.13%N/ATSHATaysha Gene Therapies-$109M-$0.38N/AN/AN/AN/A-56.07%-40.16%N/AUPBUpstream Bio-$143.44M-$2.67N/AN/AN/A-4,718.96%-41.73%-40.35%N/ALatest UPB, ANAB, TSHA, and PHVS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026UPBUpstream Bio-$0.79-$0.7470+$0.0430-$0.75$0.62 million$1.03 million5/12/2026Q1 2026ANABAnaptysBio-$0.6436-$1.84-$1.1965-$1.84$18.86 million$25.56 million5/6/2026Q1 2026TSHATaysha Gene Therapies-$0.10-$0.12-$0.02-$0.12$0.76 millionN/A4/3/2026Q4 2025PHVSPharvaris-$0.69-$0.84-$0.15-$0.84N/AN/A3/26/2026Q4 2025UPBUpstream Bio-$0.73-$0.7860-$0.0560-$0.78$0.52 million$0.67 million3/19/2026Q4 2025TSHATaysha Gene Therapies-$0.11-$0.08+$0.03-$0.08$1.89 million$5.49 million3/3/2026Q4 2025ANABAnaptysBio$0.89$1.58+$0.69$1.58$87.09 million$108.25 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANABAnaptysBioN/AN/AN/AN/AN/APHVSPharvarisN/AN/AN/AN/AN/ATSHATaysha Gene TherapiesN/AN/AN/AN/AN/AUPBUpstream BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANABAnaptysBioN/A7.589.07PHVSPharvarisN/A11.2410.11TSHATaysha Gene Therapies0.2314.0414.04UPBUpstream BioN/A26.1526.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANABAnaptysBioN/APHVSPharvarisN/ATSHATaysha Gene Therapies77.70%UPBUpstream BioN/AInsider OwnershipCompanyInsider OwnershipANABAnaptysBio33.50%PHVSPharvaris11.84%TSHATaysha Gene Therapies3.78%UPBUpstream Bio13.56%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANABAnaptysBio10029.10 million19.35 millionOptionablePHVSPharvaris3065.41 million57.66 millionNot OptionableTSHATaysha Gene Therapies180287.36 million276.50 millionOptionableUPBUpstream Bio3854.42 million47.04 millionN/AUPB, ANAB, TSHA, and PHVS HeadlinesRecent News About These CompaniesUpstream Bio (NASDAQ:UPB) Price Target Lowered to $50.00 at Mizuho2 hours ago | americanbankingnews.comUpstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue EstimatesMay 13 at 9:20 AM | zacks.comUpstream Bio Reports First Quarter 2026 Financial Results and Recent Business HighlightsMay 13 at 7:00 AM | globenewswire.comUpstream Bio, Inc. $UPB Shares Bought by UBS Group AGMay 7, 2026 | marketbeat.comJennison Associates LLC Makes New Investment in Upstream Bio, Inc. $UPBMay 3, 2026 | marketbeat.com773,148 Shares in Upstream Bio, Inc. $UPB Acquired by Pictet Asset Management Holding SAMay 2, 2026 | marketbeat.comUpstream Bio (UPB) to Release Quarterly Earnings on TuesdayApril 28, 2026 | marketbeat.comUpstream Bio, Inc. (NASDAQ:UPB) Given Consensus Recommendation of "Moderate Buy" by BrokeragesApril 22, 2026 | marketbeat.comUpstream Bio stellt neue Daten zu Verekitug auf Fachkonferenz vorApril 17, 2026 | de.investing.comUpstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International ConferenceApril 17, 2026 | globenewswire.comUpstream Bio (UPB) price target decreased by 10.31% to 44.37April 10, 2026 | msn.comValidating the IL-13/TSLP Axis: Upstream Bio’s Verekitug Positioned for Differentiated Asthma Efficacy and Favorable Risk–RewardApril 7, 2026 | tipranks.comTruist senkt Kursziel für Upstream Bio wegen verzögertem StudienzeitplanApril 2, 2026 | de.investing.comEvercore ISI stuft Upstream Bio wegen fehlender kurzfristiger Katalysatoren herabMarch 27, 2026 | de.investing.comUpstream Bio plant Phase-3-Studien für Asthma-Medikament ab Q1 2027March 26, 2026 | de.investing.comUpstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 26, 2026 | globenewswire.comUpstream Bio: CFO Gray veräußert Aktien im Wert von 7.915 US-DollarMarch 18, 2026 | de.investing.comUpstream Bio Reports Positive Phase 2 VIBRANT Trial Results for Verekitug in Chronic Rhinosinusitis with Nasal PolypsMarch 1, 2026 | quiverquant.comQUpstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual MeetingMarch 1, 2026 | globenewswire.comUpstream Bio präsentiert neue Studiendaten zu Verekitug auf AAAAI-KongressFebruary 26, 2026 | de.investing.comUpstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026February 26, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeUPB, ANAB, TSHA, and PHVS Company DescriptionsAnaptysBio NASDAQ:ANAB$62.19 -0.50 (-0.80%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$62.16 -0.03 (-0.06%) As of 05:58 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Pharvaris NASDAQ:PHVS$30.70 -2.24 (-6.80%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$30.88 +0.18 (+0.59%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.Taysha Gene Therapies NASDAQ:TSHA$6.30 -0.37 (-5.55%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$6.44 +0.14 (+2.14%) As of 05:41 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.Upstream Bio NASDAQ:UPB$8.79 -0.57 (-6.09%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$8.80 +0.01 (+0.06%) As of 06:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
